Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
60 Degrees Pharma partners with Runway Health to give international travelers direct telehealth access to once-weekly ARAKODA for malaria prevention.
-
60 DEGREES PHARMACEUTICALS, INC. ANNOUNCES APPROVAL OF REVERSE STOCK SPLIT RATIO
-
Peer-reviewed NC State study found Babesia in 24% of chronic fatigue patients, supporting further study of chronic babesiosis and ARAKODA® evaluation.
-
60 Degrees Pharmaceuticals will expand ARAKODA sales in 2026 with more reps, a GoodRx partnership, enhanced digital marketing, and added babesiosis trials
-
60 Degrees Pharma opens enrollment at Mount Sinai for its B-FREE trial testing tafenoquine in chronic babesiosis, addressing a major unmet medical need.
-
60 Degrees Pharma reports 223% YoY revenue growth in Q3 2025; advances babesiosis programs with Tulane, Mount Sinai, and MUMS canine designation plans.
-
First patient in SXTP’s relapsing babesiosis study tested negative post-tafenoquine; FDA Breakthrough request filed, Type B meeting planned 2026.
-
60 Degrees Pharma selects Mount Sinai as central site for Phase II tafenoquine trial in chronic babesiosis; enrollment starts Q4 2025, data 2026.
-
60 Degrees and Tulane to study tafenoquine against Lyme and Bartonella bacteria, part of the “3Bs” common in tick-borne illness co-infections.
-
60 Degrees closes $5M public offering with up to $5M more from short-term warrants; funds support working capital and infectious disease R&D.